ADPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Adaptive Biotechnologies Corp (ADPT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite short-term price weakness, the company's strong revenue growth, improving gross margins, reduced cash burn, and positive analyst sentiment make it a compelling long-term investment opportunity.
The stock is currently oversold with an RSI of 17.966, indicating a potential rebound. The MACD is negative but contracting, suggesting bearish momentum is weakening. The price is near a key support level at S1: 15.245, which could act as a floor for the stock.
Hedge funds are significantly increasing their positions, with a 176.86% increase in buying over the last quarter.
Strong Q4 2025 revenue growth of 63% YoY and full-year revenue growth of 55% YoY.
Positive analyst sentiment with multiple price target increases and 'Buy' ratings.
Management's optimistic guidance for 2026, including 30% growth in clonoSEQ test volumes and reduced cash burn.
The stock has experienced a recent price decline, with a -0.51% regular market change and a -3.33% post-market change.
Net income and EPS have significantly declined YoY, indicating profitability challenges.
No recent congress trading data or AI trading signals to provide additional confidence.
In Q4 2025, revenue increased by 51.04% YoY to $71.7 million, and gross margin improved to 73.98% (+21.12% YoY). However, net income dropped to -$13.58 million (-59.70% YoY), and EPS fell to -$0.09 (-60.87% YoY). The company reduced its cash burn by 68% and ended 2025 with $227 million in cash and equivalents.
Analysts are bullish on ADPT, with multiple firms raising price targets to $21-$22 and maintaining 'Buy' or 'Overweight' ratings. Analysts highlight strong growth drivers, including EMR integrations, blood-based tests, and new indications, as well as solid Q4 results and raised guidance.
